Insider Trading March 10, 2026

Astera Labs Director Executes Pre-Planned Sale of 8,000 Shares Worth $898,471

Transaction completed under a Rule 10b5-1 plan; company reported robust Q4 2025 results with 92% revenue growth

By Derek Hwang ALAB
Astera Labs Director Executes Pre-Planned Sale of 8,000 Shares Worth $898,471
ALAB

Astera Labs director Jack R. Lazar sold 8,000 common shares on March 5, 2026, through an automatic trading arrangement, generating $898,471 in proceeds. The sale occurred as the stock trades well below its 52-week peak despite a nearly 100% gain over the past year. The company also posted strong fourth-quarter 2025 results, with EPS and revenue beating expectations.

Key Points

  • Director Jack R. Lazar sold 8,000 shares on March 5, 2026, for $898,471 at prices between $118.15 and $123.50; the sale was executed under a Rule 10b5-1 plan adopted December 2, 2025.
  • Following the sale, Lazar directly owns 87,351 shares of Astera Labs, whose stock is trading about 47% below its 52-week high of $262.90 but is up 98% over the past year.
  • Astera Labs posted strong Q4 2025 results: EPS of $0.58 versus a $0.51 forecast (13.73% beat) and revenue of $270.6 million, up 92% year-over-year.

Director sale details

Jack R. Lazar, a director of Astera Labs, Inc. (NASDAQ: ALAB), completed the sale of 8,000 shares of the company's common stock on March 5, 2026, for a total of $898,471. The shares were sold at prices between $118.15 and $123.50 per share. The trades were carried out automatically under a pre-arranged Rule 10b5-1 trading plan that Lazar adopted on December 2, 2025.

Ownership after the sale

After the March 5 transactions, Lazar directly holds 87,351 shares of Astera Labs. Because the trades were executed under a Rule 10b5-1 plan, they were part of an automatic schedule rather than ad hoc, negotiated sales.

Share price context

Astera Labs shares are trading roughly 47% below their 52-week high of $262.90, yet the stock has still produced a 98% return over the last 12 months. The juxtaposition of a large year-over-year gain with a substantial gap from the 52-week top highlights ongoing volatility in the stock's trading range.

Recent financial performance

Astera Labs reported fourth-quarter 2025 results that beat expectations on the top and bottom lines. The company posted earnings per share of $0.58, ahead of the consensus forecast of $0.51, a 13.73% outperformance. Revenue for the quarter reached $270.6 million, representing year-over-year growth of 92%.

Corporate developments and analyst activity

No other major corporate actions such as mergers or acquisitions were reported in connection with the filing, and there were no recent analyst upgrades or downgrades mentioned. The report emphasizes the company’s strong quarter but does not identify new strategic moves or changes in analyst coverage.


Note: The information above reflects the transactions and financial figures reported for Astera Labs and the details provided about the director's trading plan and post-sale ownership.

Risks

  • Share-price volatility - The stock remains significantly below its 52-week high despite a large one-year gain, indicating potential price fluctuations that could affect investors and market sentiment in the technology and semiconductor-related sectors.
  • Limited near-term catalysts - No other major corporate developments, such as mergers or acquisitions, were reported and there were no noted analyst upgrades or downgrades, which may limit immediate drivers for the stock outside of operational results.
  • Interpretation of insider selling - Because the sale was executed under a pre-arranged Rule 10b5-1 plan, the transaction may not reflect current management sentiment, creating uncertainty for market participants interpreting insider activity.

More from Insider Trading

NNN REIT CEO Executes $1.49 Million Share Sale as Stock Nears Yearly High Mar 10, 2026 Alpha Teknova CEO Buys $55.8K in Company Stock; Options Awarded Earlier in February Mar 10, 2026 NexPoint Residential CFO Buys 1,000 Shares as Stock Trades Near Year Low Mar 10, 2026 Thermo Fisher CEO Executes $2.06 Million Stock Sale, Exercises Options Mar 10, 2026 Bel Fuse Executive Sells $4.49M in Class B Shares Amid Strong Quarterly Results Mar 10, 2026